Primary outcomes: cardiovascular mortality, heart failure hospitalizations; Secondary outcomes: improvement in quality of life (Kansas City Cardiomyopathy Questionnaire score), functional capacity (six-minute walk test), and biomarker levels (NT-proBNP). The gene discussed is NPPB; the disease is heart failure.